Loading company
Karyopharm Therapeutics Inc.
KPTI · Nasdaq · ·
Next earnings: November 2, 2026
$1.21-26.1%Sep 29 close
- 1M
- -35.6%
- 6M
- -77.3%
- 1Y
- -81.6%
- 5Y
- -98.8%
KPTI · Nasdaq · ·
Next earnings: November 2, 2026
$1.21-26.1%Sep 29 close
Karyopharm Therapeutics Inc. is scheduled to report next on November 2, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $33.4M | $37.9M | -11.86% |
| Profit | -$67M | -$37.3M | -79.92% |
| Profit per share | -$2.32 | -$4.32 | +46.30% |
| Free Cash Flow | -$11.8M | -$25.8M | +54.08% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our planned submission under the Accelerated Approval pathway represents the beginning of an important new chapter for Karyopharm and an important milestone for the myelofibrosis community,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Karyopharm Therapeutics Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Karyopharm Therapeutics Inc. has no earnings call transcript available.